Cost-Effectiveness of Aducanumab

<p><span data-sheets-value= "{"1":2,"2":"Dr. Brian Callaghan discusses the AAN’s comments at a recent ICER meeting on the cost-effectiveness of aducanumab, the newly approved drug for Alzheimer’s disease."}" data-sheets-userformat= "{"2":13225,"3":{"1":0},"6":{"1":[{"1":2,"2":0,"5":{"1":2,"2":0}},{"1":0,"2":0,"3":3},{"1":1,"2":0,"4":1}]},"8":{"1":[{"1":2,"2":0,"5":{"1":2,"2":0}},{"1":0,"2":0,"3":3},{"1":1,"2":0,"4":1}]},"10":2,"11":4,"12":0,"15":"Calibri, sans-serif","16":11}"> Dr. Brian Callaghan discusses the AAN’s comments at a recent ICER meeting on the cost-effectiveness of aducanumab, the newly approved drug for Alzheimer’s disease.</span></p>